The stock has recovered sharply but remains below prior highs, with the recovery still receiving fundamental confirmation from Q2 beats and raised guidance.

• Approximately 27.9% over 90 days
• Approximately 35% from the May low near $82
• Current price near $110.91
• Down approximately 13.2% YTD
• Down approximately 17.9% on a one-year total-return basis
• About 12.7% below the $127.10 YTD high
• Roughly 19% below the $137.49 52-week high
• Q2 2026 reportedly beat consensus
• Management raised its annual profit forecast based on robust demand in medical devices, cancer diagnostics, Established Pharmaceuticals, and Nutrition

↩ rebuts: “The bear is using a short-term price snapshot to dismiss a broader earnings and capital-allocation inflection.”

Revenue growth is accelerating after COVID-testing distortions, with margin recovery adding earnings leverage beyond top-line growth.

• $40.11B in 2023
• $41.95B in 2024, up 4.6%
• $44.33B in 2025, up 5.7%
• Approximately $46.58B TTM
• At 5% annual growth, revenue reaches approximately $48.9B next year and $51.4B in two years
• At 7% growth, revenue reaches approximately $49.8B next year and $53.3B in two years
• Operating margin improved from 16.3% in 2024 to 18.2% in 2025
• Gross margin increased from 55.4% to 56.4%

↩ rebuts: “The five-year revenue CAGR of approximately 0.4% is heavily distorted by the COVID-testing cycle.”

The multi-year Google Health partnership attacks the next competitive battleground in CGM by building a consumer health ecosystem around data, interpretation, personalization, and distribution.

• Multi-year Google Health partnership involving Abbott's Lingo biowearable and continuous glucose-monitoring data
• Integration of Lingo glucose data with Google's AI-driven consumer-health tools
• Conducting a large real-world metabolic-health study
• Broader consumer distribution
• Stronger data and personalization loop
• Pathway beyond traditional diabetes patients into metabolic wellness
• Additional clinical and real-world evidence supporting adoption

↩ rebuts: “DexCom's strength validates the size of the CGM category but does not automatically mean Abbott is losing share.”

The Diagnostics segment is diversifying beyond respiratory testing through oncology and molecular expansion, creating a more balanced portfolio.

• Collaboration with Exact Sciences and expansion into oncology
• Cancer diagnostics, molecular testing, immunoassay, and core laboratory systems
• Exposure to aging populations, more frequent disease detection, precision medicine, hospital and laboratory testing
• Recurring consumables and reagent demand
• Oncology and routine testing can offset respiratory testing volatility

↩ rebuts: “Respiratory-testing softness is a real segment issue but is not the whole Diagnostics story.”

Abbott's competitive moat extends across multiple healthcare categories with durable franchises, global infrastructure, and significant R&D investment.

• Category leadership and scale in CGM
• Broad cardiovascular and medical-device portfolio
• Established brands including FreeStyle Libre, Ensure, and Similac
• Global regulatory, manufacturing, and distribution capabilities
• Significant exposure to faster-growing emerging markets
• Approximately $2.94B of R&D spending in 2025, equal to roughly 6.6% of sales
• High recurring demand from devices, sensors, diagnostics, and nutritional products
• 50-plus-year record of dividend increases

Abbott's financial position is considerably stronger than the bear narrative suggests, with robust cash flow, declining leverage, and substantial shareholder returns.

• 2025 free cash flow: $7.40B
• TTM free cash flow: approximately $7.21B
• TTM FCF margin: approximately 15.5%
• 2025 operating cash flow: $9.57B
• Capital expenditure: approximately $2.17B
• Current market capitalization of approximately $191.9B
• FCF yield close to 3.9%
• Net debt: $4.41B
• Cash and equivalents: $8.52B
• Current ratio: 1.38
• Debt/equity: approximately 0.27
• Interest coverage: approximately 16x
• Net debt declined from approximately $7.78B in 2023 to $4.41B in 2025, a reduction of roughly 43%
• Approximately $4.12B in dividends
• Approximately $0.89B through buybacks
• Approximately $5.01B in total shareholder distributions
• Coverage ratio approximately 1.48 times from free cash flow
• Recent $1.35B buyback tranche covering approximately 14.0 million shares at implied average near $96

↩ rebuts: “Goodwill of approximately $24B deserves monitoring but is not presently a solvency problem with positive tangible equity, low leverage, strong interest coverage, and several billion dollars of annual free cash flow.”

The forward P/E of 18.3x is reasonable for a quality company whose earnings are normalizing, even after accounting for potential downside to estimates.

• Trailing P/E of approximately 35.9 times is elevated
• Trailing EPS of approximately $3.09 is depressed by unusual tax items and other nonrecurring effects
• Current price: approximately $110.91
• Forward EPS estimate: $6.06
• Forward P/E: 18.29 times
• A 10% reduction in the forward EPS estimate to approximately $5.45 would leave ABT trading at roughly 20 times earnings
• PEG ratio of 2.19 is not a deep-value figure
• At 20-21 times the $6.06 forward EPS estimate, base-value range is approximately $121-$127
• From $110.91, that represents roughly 9%-15% appreciation before the dividend
• Successful margin and growth re-rating toward 22 times would imply approximately $133
• Prior 52-week high near $137.49 serving as plausible bull-case recovery area
• Mid-single-digit current growth
• Strong balance sheet
• Low beta
• High free cash flow
• 2.3% dividend yield
• 50-plus-year record of dividend increases
• Exposure to defensive and secular healthcare demand

↩ rebuts: “The trailing P/E of approximately 35.9 times is clearly elevated because trailing EPS of approximately $3.09 is depressed by unusual tax items and other nonrecurring effects.”

Technical indicators support the recovery despite overbought RSI readings, with multiple moving averages and momentum signals confirming the uptrend.

• RSI at 72.60
• Price is 15.2% above the 50-day SMA
• Price is approximately 3%-4% above the 200-day SMA
• 10-day EMA at $107.60 is above both the 50-day and 200-day averages
• MACD at 3.94 is above its 3.79 signal line
• MACD histogram is positive
• Price is 4.1% above the 20-day VWMA of $106.53
• VWMA has risen sharply suggesting sustained accumulation
• ATR of $2.86, or approximately 2.6% of the share price, remains moderate
• Upper Bollinger Band at $112.16
• The 50-day SMA is still below the 200-day SMA but that is expected early in a major recovery
• Overbought is not the same as fundamentally overvalued

↩ rebuts: “The bear is making the strongest technical argument with RSI at 72.6 and the stock near the upper Bollinger Band at $112.16, but RSI measures the speed of the move, not whether the business is expensive.”

The forward P/E could be a trap if earnings normalize downward, though the 18.3x valuation remains defensible even after a 10% haircut.

• At 18.3 times the forward estimate, and still near 20 times after a 10% earnings haircut, ABT is not dependent on a hypergrowth outcome
• The valuation works with normalized earnings, not only with a perfect recovery

↩ rebuts: “The bear points to the forward P/E as potentially being a trap if earnings normalize downward.”

China, procedure volumes, and costs are legitimate risks but Abbott's diversification across four major segments helps mitigate these pressures.

• Q2's beat and raised annual profit guidance are evidence that the portfolio is currently absorbing these pressures better than the bear assumes
• If Q3 guidance is cut specifically because of deteriorating medical-device or CGM demand, the bull thesis would need to be revised

↩ rebuts: “The bear argues that China, procedure volumes, and costs will hurt results.”

DexCom competition validates the CGM market rather than proving Abbott has no competitive advantage, with Abbott's established platform, recurring-sensor model, consumer brand, and Google-backed AI strategy providing differentiation.

• Abbott has its own established CGM platform, recurring-sensor model, consumer brand
• Now has a Google-backed distribution and AI strategy
• Abbott recognized where the category is heading and is taking steps to compete beyond the sensor itself

↩ rebuts: “The bear argues that DexCom is winning the CGM market.”

Mildly bullish sentiment with low confidence is healthier than extreme optimism, with the move being supported by reported earnings and strategic developments rather than social-media frenzy.

• Supplied sentiment score is 6.2/10
• Low confidence because StockTwits was unavailable and Reddit had no relevant posts
• Absence of retail data is not bearish
• No evidence of meme-stock enthusiasm or a crowded speculative trade
• Q2 beat and raised guidance
• Google/Lingo strategic partnership
• Exact Sciences oncology collaboration
• Completed $1.35B buyback
• Defensive dividend appeal
• Positive relative sentiment versus mixed medical-device peers